Compare · DXCM vs SI
DXCM vs SI
Side-by-side comparison of DexCom Inc. (DXCM) and Shoulder Innovations Inc. (SI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and SI operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $30.09B, about 64.4x SI ($467.2M).
- Over the past year, DXCM is down 8.9% and SI is up 43.6% - SI leads by 52.5 points.
- SI has been more active in the news (9 items in the past 4 weeks vs 6 for DXCM).
- Both have 25 recent analyst ratings on file.
- Company
- DexCom Inc.
- Shoulder Innovations Inc.
- Price
- $76.65-1.74%
- $21.67-2.65%
- Market cap
- $30.09B
- $467.2M
- 1M return
- +4.76%
- +15.42%
- 1Y return
- -8.85%
- +43.61%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2005
- 2025
- News (4w)
- 6
- 9
- Recent ratings
- 25
- 25
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Shoulder Innovations Inc.
Silvergate Capital Corporation operates as a bank holding company for Silvergate Bank that provides banking products and services to business and individual clients in the United States and internationally. The company accepts deposit products, including interest and noninterest bearing demand accounts, money market and savings accounts, and certificates of deposit accounts. Its loan products comprise one-to-four family real estate loans, multi-family real estate loans, commercial real estate loans, construction loans, commercial and industrial loans, mortgage warehouse loans, and reverse mortgage loans, as well as consumer loans and other loans secured by personal property. The company also provides cash management services for digital currency-related businesses. The company was founded in 1988 and is headquartered in La Jolla, California.
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon sold $126,514 worth of shares (1,700 units at $74.42) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 104,653 units (SEC Form 4)
- Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
- Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
- Executive Chair Sayer Kevin R sold $1,926,432 worth of shares (26,756 units at $72.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 355,726 units (SEC Form 4)
- Dexcom Further Advances Vision of Glucose Biosensing for All
- Deutsche Bank initiated coverage on Dexcom with a new price target
- EVP Chief Legal Compliance Off Brown Michael Jon sold $128,435 worth of shares (1,700 units at $75.55) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,353 units (SEC Form 4)
- Director Foletta Mark G sold $296,540 worth of shares (4,000 units at $74.13) as part of a pre-agreed trading plan (SEC Form 4)
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
Latest SI
- Shoulder Innovations to Report Second Quarter 2026 Financial Results on August 6, 2026
- Director Tansey Casey M was granted 5,046 shares, increasing direct ownership by 11% to 52,712 units (SEC Form 4)
- Director Sidow Kevin K. was granted 5,046 shares, increasing direct ownership by 25% to 25,056 units (SEC Form 4)
- Director Hykes Andrew was granted 5,046 shares, increasing direct ownership by 293% to 6,769 units (SEC Form 4)
- Director Buckman Paul was granted 5,046 shares, increasing direct ownership by 9% to 63,750 units (SEC Form 4)
- Director Buchholz Richard was granted 5,046 shares, increasing direct ownership by 37% to 18,712 units (SEC Form 4)
- Shoulder Innovations Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits
- Shoulder Innovations Announces Closing of up to $50 Million Credit Facility
- Shoulder Innovations Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Chief Operating Officer Ahearn Matthew Fraser sold $374,255 worth of shares (20,000 units at $18.71) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 269,176 units (SEC Form 4)